[HTML][HTML] Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
M Chevallier, M Borgeaud, A Addeo… - World Journal of …, 2021 - ncbi.nlm.nih.gov
Lung cancer, of which non-small lung cancer is the most common subtype, represents the
leading cause of cancer related-death worldwide. It is now recognized that a significant …
leading cause of cancer related-death worldwide. It is now recognized that a significant …
Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities
Targeted therapies have changed the landscape of treatments for non-small cell lung cancer
(NSCLC). Specific targeted therapies have been approved for NSCLC patients harboring …
(NSCLC). Specific targeted therapies have been approved for NSCLC patients harboring …
Recent progress in rare oncogenic drivers and targeted therapy for non-small cell lung cancer
Y Guo, R Cao, X Zhang, L Huang, L Sun… - OncoTargets and …, 2019 - Taylor & Francis
Non-small cell lung cancer (NSCLC) is frequently associated with oncogenic driver
mutations, which play an important role in carcinogenesis and cancer progression …
mutations, which play an important role in carcinogenesis and cancer progression …
Emerging targeted therapies in advanced non-small-cell lung cancer
S Li, GS de Camargo Correia, J Wang, R Manochakian… - Cancers, 2023 - mdpi.com
Simple Summary The discovery of actionable oncogenic driver mutations in non-small-cell
lung cancer (NSCLC) has revolutionized the treatment and prognosis of this dreadful …
lung cancer (NSCLC) has revolutionized the treatment and prognosis of this dreadful …
Molecular therapeutic targets in non-small cell lung cancer
K Sankar, SM Gadgeel, A Qin - Expert review of anticancer therapy, 2020 - Taylor & Francis
Introduction Several targetable genetic alterations have been identified in non-small cell
lung cancers (NSCLC) and drugs targeting these alterations have been approved for the …
lung cancers (NSCLC) and drugs targeting these alterations have been approved for the …
Understanding and targeting resistance mechanisms in NSCLC
J Rotow, TG Bivona - Nature Reviews Cancer, 2017 - nature.com
The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …
Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion
QS Chu - Therapeutic advances in medical oncology, 2020 - journals.sagepub.com
The identification of driver mutations in epidermal growth factor receptor, anaplastic
lymphoma kinase, the BRAF and ROS1 genes and subsequent successful clinical …
lymphoma kinase, the BRAF and ROS1 genes and subsequent successful clinical …
Drug resistance to targeted therapeutic strategies in non-small cell lung cancer
Rapidly developing molecular biology techniques have been employed to identify cancer
driver genes in specimens from patients with non-small cell lung cancer (NSCLC). Inhibitors …
driver genes in specimens from patients with non-small cell lung cancer (NSCLC). Inhibitors …
Molecular targeted therapy in the treatment of advanced stage non‐small cell lung cancer (NSCLC)
N Barr Kumarakulasinghe, N Zanwijk, RA Soo - Respirology, 2015 - Wiley Online Library
Historically, patients with advanced stage non‐small cell lung cancer (NSCLC) were treated
with chemotherapy alone, but a therapeutic plateau has been reached. Advances in the …
with chemotherapy alone, but a therapeutic plateau has been reached. Advances in the …
Non-small-cell lung cancer
C Gridelli, A Rossi, DP Carbone, J Guarize… - Nature reviews Disease …, 2015 - nature.com
Lung cancer is one of the most frequently diagnosed cancers and is the leading cause of
cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous …
cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous …